Compare VGZ & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VGZ | FHTX |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 295.7M | 323.4M |
| IPO Year | 1996 | 2020 |
| Metric | VGZ | FHTX |
|---|---|---|
| Price | $2.03 | $4.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $3.75 | ★ $11.50 |
| AVG Volume (30 Days) | ★ 1.2M | 109.1K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,909,000.00 |
| Revenue This Year | N/A | $8.89 |
| Revenue Next Year | N/A | $20.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $0.88 | $3.27 |
| 52 Week High | $3.13 | $6.95 |
| Indicator | VGZ | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.63 | 43.68 |
| Support Level | $1.75 | $4.44 |
| Resistance Level | $2.46 | $5.82 |
| Average True Range (ATR) | 0.10 | 0.28 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 19.44 | 27.70 |
Vista Gold Corp operates as a development-stage company in the gold mining industry. Its flagship asset is the Mt Todd Gold Project, a development-stage gold deposit located in the Tier-1 jurisdiction of Northern Territory, Australia. Mt Todd offers a large gold mineral reserve, development optionality, expansion opportunities, exploration upside, local infrastructure, community support, and demonstrated economic feasibility. It operates in one reportable segment, consisting of acquisition, exploration and evaluation activities which are focused on Australia.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.